Author

Xing Chang

Sun Yat-sen UniversityPrimary ORCID profile (0000-0002-5072-9225 · 4 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Xing ChangiD4 papers · Westlake University

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Assay:DNA methylation· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Cheng YiiD· 1 shared Haisheng ZhangiD· 1 shared Hongsheng WangiD· 1 shared Hongxin Niu· 1 shared Jiawang Zhou· 1 shared Jiaxin He· 1 shared Ke ZhongiD· 1 shared Lijun Tao· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Cheng YiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

METTL3 inhibition-activated cGAS/STING axis enhances immunotherapy and PARP inhibitor sensitivity of lung carcinoma

Jiawang Zhou, Jiaxin He, Yunqing Lu, Cheng Yi, Xing Chang, Lijun Tao, Ke Zhong, Haisheng Zhang, Hongxin Niu, Xiansong Wang, Zhuojia Chen, Hongsheng Wang

This study shows that inhibiting METTL3 activates the cGAS/STING pathway, enhancing anti-tumor immunity and PARP inhibitor sensitivity in lung carcinoma.

Research · Jan 1, 2026Peer-reviewedCancer Biology